3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Dermatologic
1
Conditions
Keratosis, Actinic
4
Lymphoma
2
Keratosis
2
Waldenstrom Macroglobulinemia
1
Sezary Syndrome
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Neoplasms
1
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Intraocular Lymphoma
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Burkitt Lymphoma
1
Bone-Metastatic, Castration-Resistant Prostate Cancer
1
Interventions
Biopsy
8
Polymerase Chain Reaction
6
Peripheral Blood Stem Cell Transplantation
5
Epoetin Alfa
5
Sulindac
4
Microarray Analysis
4
Gene Expression Profiling
4
Cyclophosphamide
4
Colposcopy
4
Cetuximab
4
Celecoxib
4
fludarabine phosphate
3
Vaginal Smears
3
Selenium
3
Methotrexate
3
Imiquimod
3
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
3
Eflornithine
3
Darbepoetin alfa
3
Aspirin
3
Antilymphocyte Serum
3
Whole-Body Irradiation
2
Vitamin E
2
Tacrolimus
2
Radiotherapy, Intensity-Modulated
2
Methylprednisolone
2
Light Coagulation
2
Interferon-alpha
2
In Situ Hybridization, Fluorescence
2
Immunohistochemistry
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Precancerous Conditions
×
tirbanibulin
×
Clear all
NCT06135415
2026-03-25
TirbAKare
Almirall, S.A.
Phase 3
Completed
280 enrolled